Literature DB >> 21346855

Treatment of eosinophilic esophagitis: is oral viscous budesonide superior to swallowed fluticasone spray?

Somashekar G Krishna1, Bobby R Kakati, Kevin W Olden, Daniel K Brown.   

Abstract

Entities:  

Year:  2011        PMID： 21346855      PMCID： PMC3038319     

Source DB:  PubMed          Journal:  Gastroenterol Hepatol (N Y)        ISSN： 1554-7914


× No keyword cloud information.
  21 in total

1.  Pharmacokinetics and systemic activity of fluticasone via Diskus and pMDI, and of budesonide via Turbuhaler.

Authors:  L Thorsson; S Edsbäcker; A Källén; C G Löfdahl
Journal:  Br J Clin Pharmacol       Date:  2001-11       Impact factor: 4.335

2.  Oral fluticasone propionate in active distal ulcerative colitis.

Authors:  P Angus; J A Snook; M Reid; D P Jewell
Journal:  Gut       Date:  1992-05       Impact factor: 23.059

3.  Reversible formation of fatty acid esters of budesonide, an antiasthma glucocorticoid, in human lung and liver microsomes.

Authors:  A Tunek; K Sjödin; G Hallström
Journal:  Drug Metab Dispos       Date:  1997-11       Impact factor: 3.922

4.  A randomized, double-blind, placebo-controlled trial of fluticasone propionate for pediatric eosinophilic esophagitis.

Authors:  Michael R Konikoff; Richard J Noel; Carine Blanchard; Cassie Kirby; Sean C Jameson; Bridget K Buckmeier; Rachel Akers; Mitchell B Cohen; Margaret H Collins; Amal H Assa'ad; Seema S Aceves; Philip E Putnam; Marc E Rothenberg
Journal:  Gastroenterology       Date:  2006-08-16       Impact factor: 22.682

5.  Comparison of oral prednisone and topical fluticasone in the treatment of eosinophilic esophagitis: a randomized trial in children.

Authors:  Elizabeth T Schaefer; Joseph F Fitzgerald; Jean P Molleston; Joseph M Croffie; Marian D Pfefferkorn; Mark R Corkins; Joel D Lim; Steven J Steiner; Sandeep K Gupta
Journal:  Clin Gastroenterol Hepatol       Date:  2008-02       Impact factor: 11.382

Review 6.  Safety of inhaled budesonide: clinical manifestations of systemic corticosteroid-related adverse effects.

Authors:  Camilla Christensson; Anders Thorén; Bengt Lindberg
Journal:  Drug Saf       Date:  2008       Impact factor: 5.606

Review 7.  Fluticasone versus beclomethasone or budesonide for chronic asthma in adults and children.

Authors:  N Adams; T J Lasserson; C J Cates; P W Jones
Journal:  Cochrane Database Syst Rev       Date:  2007-10-17

8.  Oral viscous budesonide: a potential new therapy for eosinophilic esophagitis in children.

Authors:  Seema S Aceves; John F Bastian; Robert O Newbury; Ranjan Dohil
Journal:  Am J Gastroenterol       Date:  2007-06-20       Impact factor: 10.864

Review 9.  Budesonide for induction of remission in Crohn's disease.

Authors:  Cynthia H Seow; Eric I Benchimol; Anne Marie Griffiths; Anthony R Otley; A Hillary Steinhart
Journal:  Cochrane Database Syst Rev       Date:  2008-07-16

10.  Validation of the Mayo Dysphagia Questionnaire.

Authors:  A B M Grudell; J A Alexander; F B Enders; R Pacifico; M Fredericksen; J L Wise; G R Locke; A Arora; T Zais; N J Talley; Y Romero
Journal:  Dis Esophagus       Date:  2007       Impact factor: 3.429
View more
  6 in total

Review 1.  Management of pediatric eosinophilic esophagitis: an update.

Authors:  Seema Khan
Journal:  Paediatr Drugs       Date:  2012-02-01       Impact factor: 3.022

2.  Therapeutic options for eosinophilic esophagitis.

Authors:  Jeffrey A Alexander; David A Katzka
Journal:  Gastroenterol Hepatol (N Y)       Date:  2011-01

3.  Systematic review: adrenal insufficiency secondary to swallowed topical corticosteroids in eosinophilic oesophagitis.

Authors:  H Philpott; M K Dougherty; C C Reed; M Caldwell; D Kirk; D J Torpy; E S Dellon
Journal:  Aliment Pharmacol Ther       Date:  2018-03-05       Impact factor: 8.171

4.  Efficacy of Budesonide vs Fluticasone for Initial Treatment of Eosinophilic Esophagitis in a Randomized Controlled Trial.

Authors:  Evan S Dellon; John T Woosley; Ashley Arrington; Sarah J McGee; Jacquelyn Covington; Susan E Moist; Jessica H Gebhart; Alexandra E Tylicki; Shiyan O Shoyoye; Christopher F Martin; Joseph A Galanko; John A Baron; Nicholas J Shaheen
Journal:  Gastroenterology       Date:  2019-03-11       Impact factor: 22.682

5.  Current hurdles in the management of eosinophilic oesophagitis: the next steps.

Authors:  Stephen Ea Attwood; Michael Sj Wilson
Journal:  World J Gastroenterol       Date:  2013-02-14       Impact factor: 5.742

6.  Viscous topical is more effective than nebulized steroid therapy for patients with eosinophilic esophagitis.

Authors:  Evan S Dellon; Arif Sheikh; Olga Speck; Kimberly Woodward; Ann B Whitlow; Jessica M Hores; Marija Ivanovic; Allen Chau; John T Woosley; Ryan D Madanick; Roy C Orlando; Nicholas J Shaheen
Journal:  Gastroenterology       Date:  2012-05-03       Impact factor: 22.682
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.